Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
$0.00
$0.13
$50K1.717,603 shs35 shs
Smart for Life, Inc. stock logo
SMFL
Smart for Life
$0.00
-69.4%
$0.01
$0.00
$1.56
$23K17.056,340 shs1,949 shs
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
$0.03
+200.0%
$0.01
$0.00
$0.10
$3.80M-24.167,107 shs173 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
+11.8%
$0.19
$0.01
$26.25
$15K1.49169,058 shs1,734 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%-28.57%-50.00%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
0.00%-46.77%-89.00%+32.00%-99.79%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00%-30.23%-31.82%+29,900.00%+200.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11.82%-38.81%-94.65%-99.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/AN/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
0.00
N/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K6.16N/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
$11.11M0.00N/AN/A($17.10) per share0.00
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/A$0.11 per shareN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18MN/A0.00N/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
-$22.68MN/A0.00N/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
-$56.93M-$0.45N/AN/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19MN/A0.00N/AN/A-1,554.34%-338.29%N/A

Latest VAXX, NAVB, SMFL, and VRPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/11/2025Q3 2024
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/A-$0.94N/A-$0.94N/A$1.27 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
28.39%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
82.95%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
31.71%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
64.06%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionOptionable
Smart for Life, Inc. stock logo
SMFL
Smart for Life
1107.09 million4.84 millionNot Optionable
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
90126.75 million45.55 millionNot Optionable
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
71.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals Inc trading halted, news pending
Virpax receives positive Probudur results for dose range study
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur

New MarketBeat Followers Over Time

Media Sentiment Over Time

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

$0.0005 0.00 (0.00%)
As of 08/22/2025

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Smart for Life stock logo

Smart for Life NASDAQ:SMFL

$0.0033 -0.01 (-69.44%)
As of 08/22/2025 02:52 PM Eastern

Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.

Vaxxinity stock logo

Vaxxinity NASDAQ:VAXX

$0.03 +0.02 (+200.00%)
As of 08/22/2025 10:30 AM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

$0.01 +0.00 (+11.82%)
As of 08/22/2025 03:45 PM Eastern

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.